Addiction Disorders Drugs Market - Global Forecast 2026-2032

The Addiction Disorders Drugs Market is projected to reach USD 22.31 Billion in 2026. It is expected to continue growing at a CAGR of 9.85%, reaching USD 39.33 Billion by 2032.

The addiction disorders drugs market sits at the intersection of urgent public health need, medication-assisted treatment expansion, and fast-changing policy. Demand is driven by opioid use disorder, alcohol use disorder, tobacco dependence, stimulant use disorder, and polysubstance use, with treatment strategies spanning agonists, partial agonists, antagonists, aversive agents, withdrawal management drugs, and relapse-prevention therapies.

Commercial opportunity is strongest where evidence-based pharmacotherapy is integrated with behavioral health, primary care, telehealth, and long-term recovery support. Market leaders are increasingly focused on long-acting injectable formulations, digital adherence support, expanded access models, overdose reversal medicines, and combination care pathways that improve retention, reduce relapse, and address comorbid mental health conditions.

Transformative Shifts in Addiction Treatment

The market is being reshaped by a shift from acute detoxification to chronic disease management. Addiction is increasingly treated as a relapsing medical condition requiring sustained pharmacotherapy, coordinated behavioral care, and measurable outcomes. This shift supports broader use of buprenorphine, methadone, naltrexone, acamprosate, disulfiram, nicotine replacement therapies, varenicline, cytisine where approved, and emerging candidates for stimulant and cannabis use disorders.

Regulatory and reimbursement changes are also changing access. In the U.S., the removal of the federal X-waiver requirement for buprenorphine prescribing expanded the eligible prescriber base, while many countries are revising harm-reduction, opioid agonist therapy, and take-home medication policies. At the same time, payers and public health systems are scrutinizing real-world evidence, adherence, diversion controls, safety monitoring, and total cost-of-care benefits.

Innovation is moving beyond conventional oral therapies. Long-acting injectables and implants support adherence and reduce daily dosing burden, while intranasal overdose reversal products have increased community-based emergency response capacity. The next competitive phase will favor organizations able to prove clinical durability, safety in complex populations, compatibility with behavioral health services, and interoperability with digital and community care models.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is beginning to create cumulative value across discovery, development, access, and patient support for addiction disorder medications. In drug discovery, AI-enabled target identification, molecular screening, and biomarker analysis can help prioritize candidates for conditions with limited approved pharmacologic options, including stimulant use disorder. In clinical development, machine learning can support trial design by identifying risk profiles, predicting dropout, strengthening site selection, and improving protocol feasibility.

AI is also influencing care delivery. Predictive analytics can flag relapse risk, overdose vulnerability, treatment discontinuation, and medication nonadherence when used with validated clinical data and appropriate privacy safeguards. Natural language processing may help health systems identify substance use patterns in clinical notes, while AI-supported digital therapeutics can reinforce behavioral interventions between visits and support care coordination across primary care, psychiatry, and community programs.

The cumulative impact will depend on governance. Algorithms used in addiction care must be clinically validated, bias-tested, explainable, and transparent because substance use disorders are closely linked to stigma, criminal justice exposure, unstable housing, and other social determinants of health. Organizations that combine AI with rigorous evidence generation, patient consent, cybersecurity, and regulatory-grade data practices will be better positioned to earn provider, payer, and patient trust.

Key Regional Insights

North America remains a central market for addiction disorders drugs because of high treatment demand, established medication-assisted treatment infrastructure, and significant public funding for opioid response. The United States has the deepest commercial ecosystem for buprenorphine, naltrexone, methadone services, naloxone, alcohol use disorder medications, and smoking cessation therapies, while Canada continues to expand supervised consumption, opioid agonist therapy, and safer supply discussions in response to toxic drug supply risks.

Europe shows strong policy support for harm reduction and opioid substitution treatment, particularly in Western and Northern European health systems. European public health frameworks support surveillance, prevention, and access to evidence-based treatment, although reimbursement and prescribing rules vary by country. Asia-Pacific presents a mixed but expanding opportunity, with Japan, Australia, South Korea, China, India, and ASEAN markets showing different levels of treatment availability, stigma reduction, tobacco control policy, mental health investment, and regulatory openness.

Latin America is gaining relevance as governments address alcohol dependence, tobacco use, and illicit drug-related harms, with Brazil and Mexico acting as important demand centers. The Middle East and Africa remain underpenetrated for addiction pharmacotherapy due to stigma, specialist shortages, limited reimbursement, and uneven harm-reduction infrastructure, but GCC countries are investing in specialized behavioral health services, and parts of Africa face rising need for accessible, low-cost treatment and overdose prevention support.

Key Group Insights

Within ASEAN, addiction disorder drug demand is shaped by large populations, variable regulatory approaches, and rising focus on mental health system capacity. Access remains uneven across member states, but urban hospital networks, tobacco control programs, and public health initiatives are creating pathways for pharmacotherapy adoption, particularly for alcohol, tobacco, and opioid-related conditions where policy permits evidence-based treatment.

The GCC is increasingly relevant as governments invest in modern healthcare infrastructure, specialized psychiatric care, and national addiction treatment initiatives. Cultural stigma remains a barrier, but centralized healthcare planning can accelerate adoption of evidence-based therapies when supported by reimbursement, clinician training, confidential care pathways, and integration with broader mental health reforms. The European Union offers one of the most structured policy environments, with coordinated surveillance and harm-reduction guidance supporting long-term treatment models and cross-country evidence sharing.

BRICS countries represent high-volume opportunity, led by China, India, and Brazil, but access depends on affordability, domestic manufacturing, public-sector procurement, and regulatory alignment with evidence-based treatment standards. G7 markets provide the strongest environment for premium formulations, long-acting injectables, evidence generation, overdose reversal access, and digital care integration. NATO countries overlap significantly with North American and European markets where defense, veteran, and public health systems increasingly recognize substance use disorders as workforce, family, and community health priorities.

Key Country Insights

The United States is the most influential country market due to high opioid-related morbidity, broad medication-assisted treatment use, and active regulatory pathways for overdose reversal and relapse-prevention products. Canada is expanding harm-reduction-linked treatment capacity and opioid agonist therapy access, while Mexico and Brazil represent important Latin American markets where public-sector access, tobacco control, and alcohol-related disease burden shape demand for addiction pharmacotherapy.

In Europe, the United Kingdom, Germany, France, Italy, and Spain support mature treatment systems with varying degrees of opioid substitution therapy, alcohol use disorder medication use, and smoking cessation reimbursement. Russia has a distinct treatment environment because opioid agonist therapy is restricted, affecting market access for standard opioid use disorder medications. Germany and France are especially important for evidence-based prescribing, reimbursement evaluation, specialist care networks, and structured addiction medicine services.

China and India offer large long-term potential because of population scale, tobacco burden, alcohol-related harms, and growing investment in mental health services, but adoption depends on regulation, stigma reduction, affordability, and physician training. Japan, Australia, and South Korea offer more advanced regulatory and reimbursement environments for selected therapies, with Australia notable for harm-reduction experience and opioid pharmacotherapy access, while Japan and South Korea offer opportunities in smoking cessation, alcohol treatment, and carefully regulated addiction medicine.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize therapies that improve retention and reduce relapse, because adherence remains one of the most important barriers in addiction treatment. Long-acting injectables, depot formulations, abuse-deterrent delivery, overdose reversal products, and patient-centered dosing models should be supported with real-world evidence demonstrating fewer emergency visits, lower overdose risk, improved medication persistence, and stronger continuity of care.

Organizations should also build market access strategies around integrated care. Partnerships with primary care groups, community clinics, telehealth providers, behavioral health networks, pharmacies, harm-reduction programs, and correctional health systems can expand reach to populations that often remain outside traditional specialty treatment. Education for prescribers is essential, especially in markets where stigma and limited addiction medicine training constrain uptake.

Finally, leaders should invest in ethical AI, pharmacovigilance, and health equity. Evidence packages should include diverse populations, comorbid psychiatric conditions, pregnancy considerations where applicable, and social risk factors. Stakeholders that demonstrate safety, measurable outcomes, affordability, privacy protection, and responsible data use will be best positioned for payer acceptance and long-term public health relevance.

Research Methodology

This executive summary is based on secondary research from authoritative public health, regulatory, and scientific sources, including the World Health Organization, UN Office on Drugs and Crime, U.S. Centers for Disease Control and Prevention, U.S. Food and Drug Administration, European drug monitoring authorities, national health agencies, peer-reviewed medical literature, and published clinical guidelines.

The methodology emphasizes triangulation of epidemiology, treatment guidelines, regulatory developments, approved medication classes, policy reforms, harm-reduction practices, and regional access dynamics. Market interpretation focuses on verified disease burden, evidence-based pharmacotherapy adoption, reimbursement conditions, regulatory access, and innovation trends rather than unsupported projections.

Insights were synthesized through an industry lens, aligning clinical facts with commercial implications across regions, groups, and country markets. The analysis prioritizes data-backed statements, current treatment standards, observable policy shifts, and practical implications relevant to addiction disorders drugs.

Conclusion

The addiction disorders drugs market is evolving from fragmented treatment access toward integrated, evidence-based, and outcomes-driven care. Rising global burden, sustained overdose risk, alcohol-related harm, stimulant use concerns, and tobacco dependence continue to support demand for pharmacologic interventions that improve retention, prevent relapse, reduce withdrawal burden, and lower mortality.

Future progress will be shaped by long-acting formulations, expanded prescribing capacity, harm-reduction integration, overdose reversal access, AI-enabled patient support, and stronger real-world evidence. Organizations that combine clinical efficacy with affordability, privacy protection, equitable access, and partnerships across behavioral health ecosystems will be best positioned to lead in this high-need therapeutic area.

Additional Product Information:

Purchase of this report includes 1 year online access with quarterly updates.
This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

1. Preface

1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders

2. Research Methodology

2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations

3. Executive Summary

3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap

4. Market Overview

4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy

5. Market Insights

5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Addiction Disorders Drugs Market, by Dosage Form

7.1. Introduction
7.2. Capsule
7.3. Film
7.4. Injectable Solution
7.5. Patch
7.6. Tablet

8. Addiction Disorders Drugs Market, by Drug Class

8.1. Introduction
8.2. Alcohol
8.2.1. Acamprosate
8.2.2. Disulfiram
8.2.3. Naltrexone
8.3. Nicotine
8.4. Opioid
8.4.1. Buprenorphine
8.4.2. Methadone
8.4.3. Naltrexone

9. Addiction Disorders Drugs Market, by Product Type

9.1. Introduction
9.2. Branded
9.3. Generic

10. Addiction Disorders Drugs Market, by Administration Route

10.1. Introduction
10.2. Injectable
10.3. Oral
10.4. Sublingual
10.5. Transdermal

11. Addiction Disorders Drugs Market, by Distribution Channel

11.1. Introduction
11.2. Hospital Pharmacy
11.3. Online Pharmacy
11.4. Retail Pharmacy

12. Addiction Disorders Drugs Market, by End User

12.1. Introduction
12.2. Clinics
12.3. Homecare Settings
12.4. Hospitals

13. Addiction Disorders Drugs Market, by Region

13.1. Asia-Pacific
13.2. Europe
13.3. North America
13.4. Latin America
13.5. Africa
13.6. Middle East

14. Addiction Disorders Drugs Market, by Group

14.1. NATO
14.2. G7
14.3. BRICS
14.4. European Union
14.5. ASEAN
14.6. GCC

15. Addiction Disorders Drugs Market, by Country

15.1. China
15.2. United States
15.3. Japan
15.4. India
15.5. Germany
15.6. United Kingdom
15.7. Australia
15.8. France
15.9. South Korea
15.10. Italy
15.11. Canada
15.12. Russia
15.13. Brazil
15.14. Mexico
15.15. Spain

16. Competitive Landscape

16.1. Market Share Analysis, 2025
16.2. FPNV Positioning Matrix, 2025
16.3. Market Concentration Analysis, 2025
16.3.1. Concentration Ratio (CR)
16.3.2. Herfindahl Hirschman Index (HHI)
16.4. Recent Developments & Impact Analysis, 2025
16.5. Product Portfolio Analysis, 2025
16.6. Benchmarking Analysis, 2025

17. Company Profiles

17.1. Accord Healthcare Limited
17.2. Alkermes plc
17.3. Amneal Pharmaceuticals Inc.
17.4. Aurobindo Pharma Limited
17.5. Bausch Health Companies Inc
17.6. BioCorRx Inc.
17.7. BioDelivery Sciences International Inc
17.8. Braeburn Inc.
17.9. Camurus AB
17.10. Cipla Limited
17.11. Dr. Reddy’s Laboratories Ltd
17.12. Eli Lilly and Company
17.13. Elite Pharmaceuticals Inc.
17.14. GlaxoSmithKline PLC
17.15. Glenmark Pharmaceuticals
17.16. H. Lundbeck A/S
17.17. Hikma Pharmaceuticals PLC
17.18. Indivior PLC
17.19. Insys Therapeutics Inc
17.20. Johnson & Johnson
17.21. Mallinckrodt Pharmaceuticals PLC
17.22. Novartis AG
17.23. Orexo AB
17.24. Pear Therapeutics
17.25. Pfizer Inc
17.26. Purdue Pharma L.P.
17.27. Reckitt Benckiser Pharmaceuticals Inc
17.28. Sun Pharmaceutical Industries Ltd
17.29. Teva Pharmaceutical Industries Ltd
17.30. Titan Pharmaceuticals Inc
17.31. Viatris Inc

List of Figures

FIGURE 1. GLOBAL ADDICTION DISORDERS DRUGS MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL ADDICTION DISORDERS DRUGS MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL ADDICTION DISORDERS DRUGS MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL ADDICTION DISORDERS DRUGS MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY DOSAGE FORM, 2025 VS 2032 (%)
FIGURE 7. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY DOSAGE FORM, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2032 (%)
FIGURE 9. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2032 (%)
FIGURE 11. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025 VS 2032 (%)
FIGURE 13. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
FIGURE 15. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 17. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 19. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 21. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 23. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. GLOBAL ADDICTION DISORDERS DRUGS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 25. GLOBAL ADDICTION DISORDERS DRUGS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

List of Tables

TABLE 1. GLOBAL ADDICTION DISORDERS DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL CAPSULE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL CAPSULE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL CAPSULE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL FILM MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL FILM MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL FILM MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL INJECTABLE SOLUTION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL INJECTABLE SOLUTION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL INJECTABLE SOLUTION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL PATCH MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL PATCH MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL PATCH MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL TABLET MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL TABLET MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL TABLET MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL ALCOHOL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL ALCOHOL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL ALCOHOL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL ACAMPROSATE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL ACAMPROSATE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL ACAMPROSATE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL DISULFIRAM MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL DISULFIRAM MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL DISULFIRAM MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL NALTREXONE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL NALTREXONE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL NALTREXONE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL NICOTINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL NICOTINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL NICOTINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL OPIOID MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL OPIOID MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL OPIOID MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL BUPRENORPHINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL BUPRENORPHINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL BUPRENORPHINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL METHADONE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL METHADONE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL METHADONE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL NALTREXONE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL NALTREXONE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL NALTREXONE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL BRANDED MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL BRANDED MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL BRANDED MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL GENERIC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL GENERIC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL GENERIC MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL INJECTABLE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL INJECTABLE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL INJECTABLE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL ORAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL ORAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL SUBLINGUAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL SUBLINGUAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL SUBLINGUAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL TRANSDERMAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL TRANSDERMAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL TRANSDERMAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL ONLINE PHARMACY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL ONLINE PHARMACY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL ONLINE PHARMACY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL RETAIL PHARMACY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL RETAIL PHARMACY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL RETAIL PHARMACY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL CLINICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 79. GLOBAL CLINICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 80. GLOBAL CLINICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 81. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 82. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 83. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 84. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 85. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 86. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 87. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 88. ASIA-PACIFIC ADDICTION DISORDERS DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 89. ASIA-PACIFIC ADDICTION DISORDERS DRUGS MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 90. ASIA-PACIFIC ADDICTION DISORDERS DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 91. ASIA-PACIFIC ADDICTION DISORDERS DRUGS MARKET SIZE, BY ALCOHOL, 2017-2032 (USD MILLION)
TABLE 92. ASIA-PACIFIC ADDICTION DISORDERS DRUGS MARKET SIZE, BY OPIOID, 2017-2032 (USD MILLION)
TABLE 93. ASIA-PACIFIC ADDICTION DISORDERS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 94. ASIA-PACIFIC ADDICTION DISORDERS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 95. ASIA-PACIFIC ADDICTION DISORDERS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 96. ASIA-PACIFIC ADDICTION DISORDERS DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 97. EUROPE ADDICTION DISORDERS DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 98. EUROPE ADDICTION DISORDERS DRUGS MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 99. EUROPE ADDICTION DISORDERS DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 100. EUROPE ADDICTION DISORDERS DRUGS MARKET SIZE, BY ALCOHOL, 2017-2032 (USD MILLION)
TABLE 101. EUROPE ADDICTION DISORDERS DRUGS MARKET SIZE, BY OPIOID, 2017-2032 (USD MILLION)
TABLE 102. EUROPE ADDICTION DISORDERS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 103. EUROPE ADDICTION DISORDERS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 104. EUROPE ADDICTION DISORDERS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 105. EUROPE ADDICTION DISORDERS DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 106. NORTH AMERICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 107. NORTH AMERICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 108. NORTH AMERICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 109. NORTH AMERICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY ALCOHOL, 2017-2032 (USD MILLION)
TABLE 110. NORTH AMERICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY OPIOID, 2017-2032 (USD MILLION)
TABLE 111. NORTH AMERICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 112. NORTH AMERICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 113. NORTH AMERICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 114. NORTH AMERICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 115. LATIN AMERICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 116. LATIN AMERICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 117. LATIN AMERICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 118. LATIN AMERICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY ALCOHOL, 2017-2032 (USD MILLION)
TABLE 119. LATIN AMERICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY OPIOID, 2017-2032 (USD MILLION)
TABLE 120. LATIN AMERICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 121. LATIN AMERICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 122. LATIN AMERICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 123. LATIN AMERICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 124. AFRICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 125. AFRICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 126. AFRICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 127. AFRICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY ALCOHOL, 2017-2032 (USD MILLION)
TABLE 128. AFRICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY OPIOID, 2017-2032 (USD MILLION)
TABLE 129. AFRICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 130. AFRICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 131. AFRICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 132. AFRICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 133. MIDDLE EAST ADDICTION DISORDERS DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 134. MIDDLE EAST ADDICTION DISORDERS DRUGS MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 135. MIDDLE EAST ADDICTION DISORDERS DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 136. MIDDLE EAST ADDICTION DISORDERS DRUGS MARKET SIZE, BY ALCOHOL, 2017-2032 (USD MILLION)
TABLE 137. MIDDLE EAST ADDICTION DISORDERS DRUGS MARKET SIZE, BY OPIOID, 2017-2032 (USD MILLION)
TABLE 138. MIDDLE EAST ADDICTION DISORDERS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 139. MIDDLE EAST ADDICTION DISORDERS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 140. MIDDLE EAST ADDICTION DISORDERS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 141. MIDDLE EAST ADDICTION DISORDERS DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 142. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 143. NATO ADDICTION DISORDERS DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 144. NATO ADDICTION DISORDERS DRUGS MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 145. NATO ADDICTION DISORDERS DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 146. NATO ADDICTION DISORDERS DRUGS MARKET SIZE, BY ALCOHOL, 2017-2032 (USD MILLION)
TABLE 147. NATO ADDICTION DISORDERS DRUGS MARKET SIZE, BY OPIOID, 2017-2032 (USD MILLION)
TABLE 148. NATO ADDICTION DISORDERS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 149. NATO ADDICTION DISORDERS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 150. NATO ADDICTION DISORDERS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 151. NATO ADDICTION DISORDERS DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 152. G7 ADDICTION DISORDERS DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 153. G7 ADDICTION DISORDERS DRUGS MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 154. G7 ADDICTION DISORDERS DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 155. G7 ADDICTION DISORDERS DRUGS MARKET SIZE, BY ALCOHOL, 2017-2032 (USD MILLION)
TABLE 156. G7 ADDICTION DISORDERS DRUGS MARKET SIZE, BY OPIOID, 2017-2032 (USD MILLION)
TABLE 157. G7 ADDICTION DISORDERS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 158. G7 ADDICTION DISORDERS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 159. G7 ADDICTION DISORDERS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 160. G7 ADDICTION DISORDERS DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 161. BRICS ADDICTION DISORDERS DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 162. BRICS ADDICTION DISORDERS DRUGS MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 163. BRICS ADDICTION DISORDERS DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 164. BRICS ADDICTION DISORDERS DRUGS MARKET SIZE, BY ALCOHOL, 2017-2032 (USD MILLION)
TABLE 165. BRICS ADDICTION DISORDERS DRUGS MARKET SIZE, BY OPIOID, 2017-2032 (USD MILLION)
TABLE 166. BRICS ADDICTION DISORDERS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 167. BRICS ADDICTION DISORDERS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 168. BRICS ADDICTION DISORDERS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 169. BRICS ADDICTION DISORDERS DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 170. EUROPEAN UNION ADDICTION DISORDERS DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 171. EUROPEAN UNION ADDICTION DISORDERS DRUGS MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 172. EUROPEAN UNION ADDICTION DISORDERS DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 173. EUROPEAN UNION ADDICTION DISORDERS DRUGS MARKET SIZE, BY ALCOHOL, 2017-2032 (USD MILLION)
TABLE 174. EUROPEAN UNION ADDICTION DISORDERS DRUGS MARKET SIZE, BY OPIOID, 2017-2032 (USD MILLION)
TABLE 175. EUROPEAN UNION ADDICTION DISORDERS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 176. EUROPEAN UNION ADDICTION DISORDERS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 177. EUROPEAN UNION ADDICTION DISORDERS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 178. EUROPEAN UNION ADDICTION DISORDERS DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 179. ASEAN ADDICTION DISORDERS DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 180. ASEAN ADDICTION DISORDERS DRUGS MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 181. ASEAN ADDICTION DISORDERS DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 182. ASEAN ADDICTION DISORDERS DRUGS MARKET SIZE, BY ALCOHOL, 2017-2032 (USD MILLION)
TABLE 183. ASEAN ADDICTION DISORDERS DRUGS MARKET SIZE, BY OPIOID, 2017-2032 (USD MILLION)
TABLE 184. ASEAN ADDICTION DISORDERS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 185. ASEAN ADDICTION DISORDERS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 186. ASEAN ADDICTION DISORDERS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 187. ASEAN ADDICTION DISORDERS DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 188. GCC ADDICTION DISORDERS DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 189. GCC ADDICTION DISORDERS DRUGS MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 190. GCC ADDICTION DISORDERS DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 191. GCC ADDICTION DISORDERS DRUGS MARKET SIZE, BY ALCOHOL, 2017-2032 (USD MILLION)
TABLE 192. GCC ADDICTION DISORDERS DRUGS MARKET SIZE, BY OPIOID, 2017-2032 (USD MILLION)
TABLE 193. GCC ADDICTION DISORDERS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 194. GCC ADDICTION DISORDERS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 195. GCC ADDICTION DISORDERS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 196. GCC ADDICTION DISORDERS DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 197. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 198. CHINA ADDICTION DISORDERS DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 199. CHINA ADDICTION DISORDERS DRUGS MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 200. CHINA ADDICTION DISORDERS DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 201. CHINA ADDICTION DISORDERS DRUGS MARKET SIZE, BY ALCOHOL, 2017-2032 (USD MILLION)
TABLE 202. CHINA ADDICTION DISORDERS DRUGS MARKET SIZE, BY OPIOID, 2017-2032 (USD MILLION)
TABLE 203. CHINA ADDICTION DISORDERS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 204. CHINA ADDICTION DISORDERS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 205. CHINA ADDICTION DISORDERS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 206. CHINA ADDICTION DISORDERS DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 207. UNITED STATES ADDICTION DISORDERS DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 208. UNITED STATES ADDICTION DISORDERS DRUGS MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 209. UNITED STATES ADDICTION DISORDERS DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 210. UNITED STATES ADDICTION DISORDERS DRUGS MARKET SIZE, BY ALCOHOL, 2017-2032 (USD MILLION)
TABLE 211. UNITED STATES ADDICTION DISORDERS DRUGS MARKET SIZE, BY OPIOID, 2017-2032 (USD MILLION)
TABLE 212. UNITED STATES ADDICTION DISORDERS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 213. UNITED STATES ADDICTION DISORDERS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 214. UNITED STATES ADDICTION DISORDERS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 215. UNITED STATES ADDICTION DISORDERS DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 216. JAPAN ADDICTION DISORDERS DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 217. JAPAN ADDICTION DISORDERS DRUGS MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 218. JAPAN ADDICTION DISORDERS DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 219. JAPAN ADDICTION DISORDERS DRUGS MARKET SIZE, BY ALCOHOL, 2017-2032 (USD MILLION)
TABLE 220. JAPAN ADDICTION DISORDERS DRUGS MARKET SIZE, BY OPIOID, 2017-2032 (USD MILLION)
TABLE 221. JAPAN ADDICTION DISORDERS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 222. JAPAN ADDICTION DISORDERS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 223. JAPAN ADDICTION DISORDERS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 224. JAPAN ADDICTION DISORDERS DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 225. INDIA ADDICTION DISORDERS DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 226. INDIA ADDICTION DISORDERS DRUGS MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 227. INDIA ADDICTION DISORDERS DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 228. INDIA ADDICTION DISORDERS DRUGS MARKET SIZE, BY ALCOHOL, 2017-2032 (USD MILLION)
TABLE 229. INDIA ADDICTION DISORDERS DRUGS MARKET SIZE, BY OPIOID, 2017-2032 (USD MILLION)
TABLE 230. INDIA ADDICTION DISORDERS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 231. INDIA ADDICTION DISORDERS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 232. INDIA ADDICTION DISORDERS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 233. INDIA ADDICTION DISORDERS DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 234. GERMANY ADDICTION DISORDERS DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 235. GERMANY ADDICTION DISORDERS DRUGS MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 236. GERMANY ADDICTION DISORDERS DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 237. GERMANY ADDICTION DISORDERS DRUGS MARKET SIZE, BY ALCOHOL, 2017-2032 (USD MILLION)
TABLE 238. GERMANY ADDICTION DISORDERS DRUGS MARKET SIZE, BY OPIOID, 2017-2032 (USD MILLION)
TABLE 239. GERMANY ADDICTION DISORDERS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 240. GERMANY ADDICTION DISORDERS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 241. GERMANY ADDICTION DISORDERS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 242. GERMANY ADDICTION DISORDERS DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 243. UNITED KINGDOM ADDICTION DISORDERS DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 244. UNITED KINGDOM ADDICTION DISORDERS DRUGS MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 245. UNITED KINGDOM ADDICTION DISORDERS DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 246. UNITED KINGDOM ADDICTION DISORDERS DRUGS MARKET SIZE, BY ALCOHOL, 2017-2032 (USD MILLION)
TABLE 247. UNITED KINGDOM ADDICTION DISORDERS DRUGS MARKET SIZE, BY OPIOID, 2017-2032 (USD MILLION)
TABLE 248. UNITED KINGDOM ADDICTION DISORDERS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 249. UNITED KINGDOM ADDICTION DISORDERS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 250. UNITED KINGDOM ADDICTION DISORDERS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 251. UNITED KINGDOM ADDICTION DISORDERS DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 252. AUSTRALIA ADDICTION DISORDERS DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 253. AUSTRALIA ADDICTION DISORDERS DRUGS MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 254. AUSTRALIA ADDICTION DISORDERS DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 255. AUSTRALIA ADDICTION DISORDERS DRUGS MARKET SIZE, BY ALCOHOL, 2017-2032 (USD MILLION)
TABLE 256. AUSTRALIA ADDICTION DISORDERS DRUGS MARKET SIZE, BY OPIOID, 2017-2032 (USD MILLION)
TABLE 257. AUSTRALIA ADDICTION DISORDERS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 258. AUSTRALIA ADDICTION DISORDERS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 259. AUSTRALIA ADDICTION DISORDERS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 260. AUSTRALIA ADDICTION DISORDERS DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 261. FRANCE ADDICTION DISORDERS DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 262. FRANCE ADDICTION DISORDERS DRUGS MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 263. FRANCE ADDICTION DISORDERS DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 264. FRANCE ADDICTION DISORDERS DRUGS MARKET SIZE, BY ALCOHOL, 2017-2032 (USD MILLION)
TABLE 265. FRANCE ADDICTION DISORDERS DRUGS MARKET SIZE, BY OPIOID, 2017-2032 (USD MILLION)
TABLE 266. FRANCE ADDICTION DISORDERS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 267. FRANCE ADDICTION DISORDERS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 268. FRANCE ADDICTION DISORDERS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 269. FRANCE ADDICTION DISORDERS DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 270. SOUTH KOREA ADDICTION DISORDERS DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 271. SOUTH KOREA ADDICTION DISORDERS DRUGS MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 272. SOUTH KOREA ADDICTION DISORDERS DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 273. SOUTH KOREA ADDICTION DISORDERS DRUGS MARKET SIZE, BY ALCOHOL, 2017-2032 (USD MILLION)
TABLE 274. SOUTH KOREA ADDICTION DISORDERS DRUGS MARKET SIZE, BY OPIOID, 2017-2032 (USD MILLION)
TABLE 275. SOUTH KOREA ADDICTION DISORDERS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 276. SOUTH KOREA ADDICTION DISORDERS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 277. SOUTH KOREA ADDICTION DISORDERS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 278. SOUTH KOREA ADDICTION DISORDERS DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 279. ITALY ADDICTION DISORDERS DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 280. ITALY ADDICTION DISORDERS DRUGS MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 281. ITALY ADDICTION DISORDERS DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 282. ITALY ADDICTION DISORDERS DRUGS MARKET SIZE, BY ALCOHOL, 2017-2032 (USD MILLION)
TABLE 283. ITALY ADDICTION DISORDERS DRUGS MARKET SIZE, BY OPIOID, 2017-2032 (USD MILLION)
TABLE 284. ITALY ADDICTION DISORDERS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 285. ITALY ADDICTION DISORDERS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 286. ITALY ADDICTION DISORDERS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 287. ITALY ADDICTION DISORDERS DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 288. CANADA ADDICTION DISORDERS DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 289. CANADA ADDICTION DISORDERS DRUGS MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 290. CANADA ADDICTION DISORDERS DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 291. CANADA ADDICTION DISORDERS DRUGS MARKET SIZE, BY ALCOHOL, 2017-2032 (USD MILLION)
TABLE 292. CANADA ADDICTION DISORDERS DRUGS MARKET SIZE, BY OPIOID, 2017-2032 (USD MILLION)
TABLE 293. CANADA ADDICTION DISORDERS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 294. CANADA ADDICTION DISORDERS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 295. CANADA ADDICTION DISORDERS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 296. CANADA ADDICTION DISORDERS DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 297. RUSSIA ADDICTION DISORDERS DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 298. RUSSIA ADDICTION DISORDERS DRUGS MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 299. RUSSIA ADDICTION DISORDERS DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 300. RUSSIA ADDICTION DISORDERS DRUGS MARKET SIZE, BY ALCOHOL, 2017-2032 (USD MILLION)
TABLE 301. RUSSIA ADDICTION DISORDERS DRUGS MARKET SIZE, BY OPIOID, 2017-2032 (USD MILLION)
TABLE 302. RUSSIA ADDICTION DISORDERS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 303. RUSSIA ADDICTION DISORDERS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 304. RUSSIA ADDICTION DISORDERS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 305. RUSSIA ADDICTION DISORDERS DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 306. BRAZIL ADDICTION DISORDERS DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 307. BRAZIL ADDICTION DISORDERS DRUGS MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 308. BRAZIL ADDICTION DISORDERS DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 309. BRAZIL ADDICTION DISORDERS DRUGS MARKET SIZE, BY ALCOHOL, 2017-2032 (USD MILLION)
TABLE 310. BRAZIL ADDICTION DISORDERS DRUGS MARKET SIZE, BY OPIOID, 2017-2032 (USD MILLION)
TABLE 311. BRAZIL ADDICTION DISORDERS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 312. BRAZIL ADDICTION DISORDERS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 313. BRAZIL ADDICTION DISORDERS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 314. BRAZIL ADDICTION DISORDERS DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 315. MEXICO ADDICTION DISORDERS DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 316. MEXICO ADDICTION DISORDERS DRUGS MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 317. MEXICO ADDICTION DISORDERS DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 318. MEXICO ADDICTION DISORDERS DRUGS MARKET SIZE, BY ALCOHOL, 2017-2032 (USD MILLION)
TABLE 319. MEXICO ADDICTION DISORDERS DRUGS MARKET SIZE, BY OPIOID, 2017-2032 (USD MILLION)
TABLE 320. MEXICO ADDICTION DISORDERS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 321. MEXICO ADDICTION DISORDERS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 322. MEXICO ADDICTION DISORDERS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 323. MEXICO ADDICTION DISORDERS DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 324. SPAIN ADDICTION DISORDERS DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 325. SPAIN ADDICTION DISORDERS DRUGS MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 326. SPAIN ADDICTION DISORDERS DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 327. SPAIN ADDICTION DISORDERS DRUGS MARKET SIZE, BY ALCOHOL, 2017-2032 (USD MILLION)
TABLE 328. SPAIN ADDICTION DISORDERS DRUGS MARKET SIZE, BY OPIOID, 2017-2032 (USD MILLION)
TABLE 329. SPAIN ADDICTION DISORDERS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 330. SPAIN ADDICTION DISORDERS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 331. SPAIN ADDICTION DISORDERS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 332. SPAIN ADDICTION DISORDERS DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 333. GLOBAL ADDICTION DISORDERS DRUGS MARKET SHARE, BY KEY PLAYER, 2025
TABLE 334. GLOBAL ADDICTION DISORDERS DRUGS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

Companies Mentioned

Accord Healthcare Limited
Alkermes plc
Amneal Pharmaceuticals Inc.
Aurobindo Pharma Limited
Bausch Health Companies Inc
BioCorRx Inc.
BioDelivery Sciences International Inc
Braeburn Inc.
Camurus AB
Cipla Limited
Dr. Reddy’s Laboratories Ltd
Eli Lilly and Company
Elite Pharmaceuticals Inc.
GlaxoSmithKline PLC
Glenmark Pharmaceuticals
H. Lundbeck A/S
Hikma Pharmaceuticals PLC
Indivior PLC
Insys Therapeutics Inc
Johnson & Johnson
Mallinckrodt Pharmaceuticals PLC
Novartis AG
Orexo AB
Pear Therapeutics
Pfizer Inc
Purdue Pharma L.P.
Reckitt Benckiser Pharmaceuticals Inc
Sun Pharmaceutical Industries Ltd
Teva Pharmaceutical Industries Ltd
Titan Pharmaceuticals Inc
Viatris Inc

Table Information

Report Attribute	Details
No. of Pages	199
Published	August 2026
Forecast Period	2026 - 2032
Estimated Market Value ( USD ) in 2026	$ 22.31 Billion
Forecasted Market Value ( USD ) by 2032	$ 39.33 Billion
Compound Annual Growth Rate	9.8%
Regions Covered	Global
No. of Companies Mentioned	31

License	Format	Properties	Price
1 - 5 USER LICENSE PDF, Excel and Online Access		This is a 1-5 user license, allowing up to five users have access to the product.	€3184EUR$3,545USD£2,720GBP €3538EUR$3,939USD£3,022GBP
ENTERPRISE LICENSE PDF, Excel and Online Access		This is an enterprise license, allowing all employees within your organization access to the product.	€4817EUR$5,363USD£4,115GBP €5352EUR$5,959USD£4,572GBP

Transformative Shifts in Addiction Treatment

Cumulative Impact of Artificial Intelligence

Key Regional Insights

Key Group Insights

Key Country Insights

Actionable Recommendations for Industry Leaders

Research Methodology

Conclusion

Table of Contents

Companies Mentioned

Table Information

Related Topics

Related Reports

Addictions Therapeutics Market Report 2026

Drug Addiction Treatment Market Report 2026

Addiction Therapeutics - Global Strategic Business Report

Addiction Treatment - Global Strategic Business Report

Addiction Treatment Market Report: Trends, Forecast and Competitive Analysis to 2031